Exploration of the protection of riboflavin laurate on oral mucositis induced by chemotherapy or radiotherapy at the cellular level: what is the leading contributor?

Zixue Xuan; Yinghong An; Dexuan Yang; Shanshan Wang; Qishou Xu; Shoujun Yuan

doi:10.3390/ijms14034722

Exploration of the protection of riboflavin laurate on oral mucositis induced by chemotherapy or radiotherapy at the cellular level: what is the leading contributor?

Int J Mol Sci. 2013 Feb 27;14(3):4722-33. doi: 10.3390/ijms14034722.

Authors

Zixue Xuan¹, Yinghong An, Dexuan Yang, Shanshan Wang, Qishou Xu, Shoujun Yuan

Affiliation

¹ School of Graduate Studies, Anhui Medical University, Hefei 230032, Anhui, China. yuansj@nic.bmi.ac.cn.

Abstract

Oral or gastrointestinal mucositis is a frequent phenomenon in cancer patients receiving chemotherapy or radiotherapy. In addition, several clinical investigations have demonstrated in recent years that riboflavin laurate has the potential to protect the patients from the disease induced by chemotherapy or radiotherapy. In our studies, it is observed that riboflavin laurate can ameliorate either chemotherapy- or radiotherapy-induced toxicities on Helf cells, and the effect is greater than that of riboflavin. In addition, riboflavin laurate is able to transport through the Caco-2 cell monolayer as the prototype, indicating the protective effects may be produced by the prototype of riboflavin laurate, rather than simply by the released riboflavin.